Nasdaq:ANEB
Anebulo Pharmaceuticals, Inc.
A clinical-stage biopharma firm targeting rare diseases with $11.6M in cash, pursuing strategic M&A to monetize a drug discovery pipeline.
Key Metrics
Investment Thesis
Bull Case
An investor might consider the stock for its high-risk, high-reward profile as a pure-play biotech company with zero revenue but substantial cash reserves relative to its small asset base of $12.1M. The potential for value creation lies in successful strategic acquisitions that can immediately generate pipeline assets and diversify revenue streams beyond the current clinical development stage.
Bear Case
The stock carries extreme downside risk due to a cumulative retained earnings deficit of $73.9M and a consistent net loss trend from -$11.7M in 2023 to -$8.5M in 2025 without any path to profitability visible yet. With total liabilities approaching half of shareholders equity and no commercial products, the company faces an imminent risk of insolvency if it cannot secure additional capital or achieve a breakthrough clinical milestone soon.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases and orphan indications, primarily serving patients in the United States through partnerships with academic institutions and contract research organizations. The company currently operates without commercial revenue while directing its limited liquidity toward high-value R&D projects and strategic asset acquisition to build a pipeline of differentiated treatments.
Analysis
Management Discussion
Management successfully preserved cash levels by maintaining a positive net change in cash of $8.5M despite reporting a net loss of $8.5M, primarily driven by heavy investments in R&D and operating expenses totaling $9.2M. The company utilized financing activities including $14.9M in cash flow from financing to offset operational burn, resulting in an ending cash balance that matches beginning cash plus net change, indicating effective short-term liquidity management.
Industry Overview
The biopharmaceutical industry for rare diseases is characterized by high R&D costs, long development timelines, and significant regulatory uncertainty but offers substantial rewards through orphan drug exclusivity periods and premium pricing. Companies in this sector often rely on strategic partnerships and M&A to de-risk their portfolios, making capital efficiency a critical survival metric.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $11.8M | $8.3M | $9.2M |
| Operating Income | $-11.8M | $-8.3M | $-9.2M |
| R&D | $5.6M | $3.5M | $4.3M |
| G&A | $6.2M | $4.8M | $4.9M |
| Stock-Based Comp | $884.7K | $758.9K | $1.4M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | — | — | $400.0K |
| Interest Income | $92.4K | $249.0K | $257.9K |
| Pre-Tax Income | $-11.8M | $-8.3M | $-9.2M |
| Income Tax | $-51.3K | $-107.1K | $-738.7K |
| Continuing Ops | $-11.7M | $-8.2M | $-8.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-11.7M | $-8.2M | $-8.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-11.7M | $-8.2M | $-8.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | — | $3.5M | $12.0M |
| Cash & Equivalents | — | $3.1M | $11.6M |
| Other Current Assets | — | $413.8K | $334.7K |
| Long-Term Assets | — | $565.1K | $183.1K |
| Total Assets | $11.7M | $4.1M | $12.1M |
| Accounts Payable | $534.5K | $156.4K | $224.2K |
| Total Liabilities | $1.1M | $260.6K | $487.7K |
| Shareholders' Equity | $10.6M | $3.8M | $11.7M |
| Paid-In Capital | $67.8M | $69.2M | $85.5M |
| Retained Earnings | $-57.2M | $-65.4M | $-73.9M |
| Total L&E | $11.7M | $4.1M | $12.1M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-11.7M | $-8.2M | $-8.5M |
| Non-Cash Adjustments | $2.1M | $928.0K | $2.1M |
| Working Capital Changes | $-51.9K | $-817.2K | $74.8K |
| Cash from Operations | $-9.7M | $-8.1M | $-6.3M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $6.4M | $-62.4K | $14.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-3.3M | $-8.2M | $8.5M |
| Beginning Cash | $14.5M | $11.2M | $3.1M |
| Ending Cash | $11.2M | $3.1M | $11.6M |
Frequently Asked Questions
How does Anebulo Pharmaceuticals, Inc. make money?
The company's operations are currently consolidated into a single clinical development segment where all financial activity is directed toward research and development costs ($4.3M), general and administrative expenses ($4.9M), and share-based compensation ($1.4M) rather than commercial sales revenue, which remains at zero.
What are the main risks for ANEB?
Complete reliance on future equity or debt financing to sustain operations given the lack of commercial revenue stream, significant dilution risk from recent common share issuances totaling $15M, potential failure of clinical trials due to scientific hurdles, and concentration risk in a small market segment for rare diseases with limited payer coverage.
What is ANEB's competitive advantage?
Access to unique intellectual property through strategic M&A partnerships, a lean operational structure minimizing overhead burn, and a specialized focus on high-value orphan diseases that often qualify for expedited regulatory pathways like FDA Fast Track designation.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.